Eosinophilic Esophagitis – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)

Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus caused by an accumulation of eosinophils, which leads to difficulty in swallowing food and the potential for dangerous food impaction. Topical steroids and proton pump inhibitors are the mainstays of clinical management for EoE; however, the indication has no FDA-approved therapy. EoE has an active pipeline; Takeda’s budesonide oral suspension is under FDA priority review, and both Sanofi / Regeneron’s Dupixent and AstraZeneca’s Fasenra are in Phase III development. As the EoE treatment landscape evolves, this report offers insights from real-world claims data into prescribing trends in EoE to help developers better understand current treatment practices and to help define the market niche for their emerging product.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed EoE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed EoE patients? ·
  • How have steroids and proton pump inhibitors been integrated into the treatment algorithm, and what are their sources of business? ·
  • What percentage of EoE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis? ·
  • What percentage of EoE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? ·
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Various

Key drugs: Omeprazole, Pantoprazole, Fluticasone Propionate, Montelukast, Prednisone, Prednisolone, Lansoprazole, Budesonide, Ranitidine

Table of contents

  • Eosinophilic Esophagitis - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms CDA Eosinophilic Esophagitis US May 2021
    • Treatment Algorithms CDA Eosinophilic Esophagitis US 2021 Dashboard

launch Related Market Assessment Reports